Serum CTGF in Chronic Plantar Fasciitis

NCT07785453 | Not Yet Recruiting

• 1 other identifier: PF-CTGF-2026-01
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This observational study aims to evaluate serum Connective Tissue Growth Factor (CTGF/CCN2) levels in patients with chronic plantar fasciitis compared with asymptomatic controls. The study will also assess the associations between serum CTGF levels and clinical and ultrasonographic characteristics of chronic plantar fasciitis.

Conditions

Plantar Fasciitis

Outcome Measures

Primary Outcomes (1)

• Serum CTGF/CCN2 Level

  Serum Connective Tissue Growth Factor (CTGF/CCN2) levels will be measured in patients with chronic plantar fasciitis and asymptomatic controls.

  At baseline

Secondary Outcomes (3)

• Pain Severity

  At baseline

• Foot Function Index

  At baseline

• Plantar Fascia Thickness

  At baseline

Study Arms (2)

Chronic Plantar Fasciitis Group

Patients with chronic plantar fasciitis diagnosed based on clinical and ultrasonographic evaluation.

Control Group

Asymptomatic participants without clinical or ultrasonographic findings of plantar fasciitis.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults aged 18-65 years, including patients with chronic plantar fasciitis and asymptomatic controls without clinical or ultrasonographic findings of plantar fasciitis.

You may qualify if:

• Age 18-65 years.
• Written informed consent.
• For the patient group: chronic plantar heel pain for at least 3 months, pain during the first steps in the morning or after prolonged rest, tenderness over the medial calcaneal tubercle, and clinical and ultrasonographic findings consistent with chronic plantar fasciitis.
• For the control group: asymptomatic individuals without a previous diagnosis or clinical and ultrasonographic findings of plantar fasciitis.

You may not qualify if:

• Tarsal tunnel syndrome, calcaneal stress fracture, plantar fascia rupture, Achilles tendinopathy, heel fat pad syndrome, plantar fibromatosis, or other foot conditions causing plantar heel pain.
• Diabetes mellitus.
• Inflammatory rheumatic diseases or gout.
• Chronic kidney or liver disease.
• Malignancy.
• Active infection or autoimmune disease
• Pregnancy.
• Previous foot or ankle surgery.
• Corticosteroid injection, platelet-rich plasma (PRP), prolotherapy, extracorporeal shock wave therapy (ESWT), or other interventional treatment to the affected heel within the previous 3 months.
• Serious systemic conditions that may affect serum CTGF/CCN2 levels.

Sponsors & Collaborators

• Kanuni Sultan Suleyman Training and Research Hospital: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum samples collected from participants for measurement of CTGF/CCN2 levels.

MeSH Terms

Conditions

Fasciitis, Plantar

Condition Hierarchy (Ancestors)

Fasciitis; Musculoskeletal Diseases; Foot Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Physical Medicine and Rehabilitation Specialist

Study Record Dates

• First Submitted: August 21, 2026
• First Posted: August 25, 2026
• Study Start: August 30, 2026
• Primary Completion (Estimated): October 30, 2026
• Study Completion (Estimated): November 15, 2026
• Last Updated: August 25, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share